EP3407888A4 - Composés organiques - Google Patents
Composés organiques Download PDFInfo
- Publication number
- EP3407888A4 EP3407888A4 EP17744910.5A EP17744910A EP3407888A4 EP 3407888 A4 EP3407888 A4 EP 3407888A4 EP 17744910 A EP17744910 A EP 17744910A EP 3407888 A4 EP3407888 A4 EP 3407888A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- organic compounds
- compounds
- organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK20215786.3T DK3838274T3 (da) | 2016-01-26 | 2017-01-26 | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-derivat til brug til behandling af cns-lidelser |
EP20215786.3A EP3838274B1 (fr) | 2016-01-26 | 2017-01-26 | Dérivé de pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline pour son utilisation dans les traitements de troubles du snc |
PL17744910T PL3407888T3 (pl) | 2016-01-26 | 2017-01-26 | Związki pirydopirolochinoksaliny, ich kompozycje i zastosowania |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662287264P | 2016-01-26 | 2016-01-26 | |
US201662440130P | 2016-12-29 | 2016-12-29 | |
PCT/US2017/015178 WO2017132408A1 (fr) | 2016-01-26 | 2017-01-26 | Composés organiques |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20215786.3A Division EP3838274B1 (fr) | 2016-01-26 | 2017-01-26 | Dérivé de pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline pour son utilisation dans les traitements de troubles du snc |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3407888A1 EP3407888A1 (fr) | 2018-12-05 |
EP3407888A4 true EP3407888A4 (fr) | 2019-06-26 |
EP3407888B1 EP3407888B1 (fr) | 2020-12-30 |
Family
ID=59398657
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20215786.3A Active EP3838274B1 (fr) | 2016-01-26 | 2017-01-26 | Dérivé de pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline pour son utilisation dans les traitements de troubles du snc |
EP17744910.5A Active EP3407888B1 (fr) | 2016-01-26 | 2017-01-26 | Composés pyridopyrroloquinoxaliniques, leurs compositions et utilisations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20215786.3A Active EP3838274B1 (fr) | 2016-01-26 | 2017-01-26 | Dérivé de pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline pour son utilisation dans les traitements de troubles du snc |
Country Status (17)
Country | Link |
---|---|
US (4) | US10245260B2 (fr) |
EP (2) | EP3838274B1 (fr) |
JP (3) | JP6995761B2 (fr) |
KR (1) | KR20180099905A (fr) |
CN (2) | CN108883111B (fr) |
AU (1) | AU2017211791B2 (fr) |
BR (1) | BR112018015283B1 (fr) |
CA (1) | CA3011983A1 (fr) |
DK (2) | DK3407888T3 (fr) |
ES (2) | ES2969145T3 (fr) |
HU (2) | HUE064667T2 (fr) |
IL (3) | IL296884B2 (fr) |
MX (2) | MX2018009158A (fr) |
PL (2) | PL3407888T3 (fr) |
PT (2) | PT3838274T (fr) |
RU (1) | RU2743513C2 (fr) |
WO (1) | WO2017132408A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105168219B (zh) * | 2008-05-27 | 2018-11-20 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
RU2014145682A (ru) | 2012-04-14 | 2016-06-10 | Интра-Селлулар Терапиз, Инк | Органические соединения |
EP2968320B1 (fr) | 2013-03-15 | 2020-11-11 | Intra-Cellular Therapies, Inc. | Composés organiques |
WO2015085004A1 (fr) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Nouveaux procédés |
KR20220054908A (ko) | 2014-04-04 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
IL296884B2 (en) | 2016-01-26 | 2024-05-01 | Intra Cellular Therapies Inc | Condensed heterocyclic converted gamma carbonyls for use in the treatment of central nervous system disorders |
CN113754661A (zh) | 2016-03-25 | 2021-12-07 | 细胞内治疗公司 | 有机化合物 |
EP3436083A4 (fr) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | Nouvelles compositions et méthodes |
WO2018071233A1 (fr) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Dispersions solides amorphes |
US10961245B2 (en) * | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
WO2018126143A1 (fr) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Composés organiques |
BR112019019875A2 (pt) | 2017-03-24 | 2020-04-22 | Intra Cellular Therapies Inc | novas composições e métodos |
EP3658144B1 (fr) * | 2017-07-26 | 2022-01-26 | Intra-Cellular Therapies, Inc. | Composés pyridopyrroloquinoxalines, leurs compositions et utilisations en thérapie |
US11376249B2 (en) | 2017-07-26 | 2022-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2019178484A1 (fr) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Nouveaux procédés |
US20210009592A1 (en) * | 2018-03-23 | 2021-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN112040940A (zh) * | 2018-03-23 | 2020-12-04 | 细胞内治疗公司 | 有机化合物 |
CA3102948A1 (fr) * | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Nouvelles methodes |
KR20210031455A (ko) | 2018-06-11 | 2021-03-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
CN112166520A (zh) | 2018-06-15 | 2021-01-01 | 株式会社Lg化学 | 固体电解质膜和包含该固体电解质膜的固态电池 |
US10695345B2 (en) | 2018-08-31 | 2020-06-30 | Intra-Cellular Therapies, Inc. | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
CN113423568A (zh) * | 2018-12-17 | 2021-09-21 | 细胞内治疗公司 | 有机化合物 |
BR112021011854A2 (pt) * | 2018-12-17 | 2021-09-08 | Intra-Cellular Therapies, Inc. | Síntese de gama-carbolinas heterocíclicas fundidas substituídas |
US20220064166A1 (en) * | 2018-12-17 | 2022-03-03 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
JP7377871B2 (ja) | 2018-12-21 | 2023-11-10 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
US20220048910A1 (en) * | 2018-12-21 | 2022-02-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
KR20210118889A (ko) * | 2019-01-23 | 2021-10-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 중독 치료 방법 |
WO2020206391A1 (fr) * | 2019-04-04 | 2020-10-08 | Intra-Cellular Therapies, Inc. | Méthodes de traitement de la douleur neuropathique |
JP2022549335A (ja) * | 2019-09-25 | 2022-11-24 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
EP4072554A4 (fr) | 2019-12-11 | 2023-12-20 | Intra-Cellular Therapies, Inc. | Composé organique |
BR112023005443A2 (pt) * | 2020-10-09 | 2023-05-09 | Shujing Biopharma Co Ltd | Derivado de y-carbolina fundido substituído heterocíclico, método de preparação do mesmo, intermediário do mesmo e uso do mesmo |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011133224A1 (fr) * | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Composés organiques |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
US4136145A (en) | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
SE8304361D0 (sv) | 1983-08-10 | 1983-08-10 | Ferrosan Ab | Novel 1-acylpiperazine derivatives novel 1-acylpiperazine derivatives |
CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
AU6541786A (en) | 1985-10-09 | 1987-05-05 | Desitin Arzneimittel Gmbh | Process for producing an administration or dosage form of drugs, reagents or other active ingredients |
ZA871987B (en) | 1986-03-19 | 1988-05-25 | Kumiai Chemical Industry Co | 5h-1,3,4-thiadiazole(3,2-a)pyrimidin-5-one derivatives and fungicidal compositions containing the same |
JP2641443B2 (ja) | 1986-04-07 | 1997-08-13 | クミアイ化学工業株式会社 | 5H−1,3,4−チアジアゾロ〔3,2−a〕ピリミジン−5−オン誘導体及びこれを有効成分とする農園芸用殺菌剤 |
HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
DE4018247A1 (de) | 1990-06-07 | 1991-12-12 | Lohmann Therapie Syst Lts | Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen |
IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
ATE288270T1 (de) | 1993-11-19 | 2005-02-15 | Janssen Pharmaceutica Nv | Mikroverkapselte 1,2-benzazole |
HU225051B1 (en) | 1994-03-02 | 2006-05-29 | Organon Ireland Ltd | Sublingual or buccal pharmaceutical compositions containing trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
WO1999018057A1 (fr) | 1997-10-06 | 1999-04-15 | Massachusetts Institute Of Technology | Preparation de diaryl ethers par reactions de condensation |
US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
DE69904448T2 (de) | 1998-02-26 | 2003-10-23 | Massachusetts Inst Technology | Metallkatalysierte arylierungen und vinylierungen von hydrazinen, hydrazonen, hydroxylaminen und oximen |
US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
JP5035813B2 (ja) | 1998-07-10 | 2012-09-26 | マサチューセッツ インスティテュート オブ テクノロジー | 金属用のリガンドおよびそれらに基づいて改善された金属触媒法 |
US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
DE69915346T2 (de) | 1998-12-17 | 2004-07-22 | Alza Corp., Mountain View | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
PE20010052A1 (es) | 1999-04-23 | 2001-01-27 | Upjohn Co | Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht |
DE60014083T2 (de) | 1999-06-15 | 2006-03-02 | Bristol-Myers Squibb Pharma Co., Wilmington | Substituierte heterocyclylkondensierte gamma carboline |
US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
US7071186B2 (en) * | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
DE60001623T2 (de) | 1999-12-03 | 2003-12-18 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
WO2002059129A2 (fr) | 2000-12-20 | 2002-08-01 | Bristol-Myers Squibb Company | Pyridoindoles substitues en tant qu'agonistes et antagonistes de serotonine |
US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
DK1390340T3 (en) | 2001-04-24 | 2017-05-15 | Massachusetts Inst Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
DE60206636T2 (de) | 2001-08-08 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | THERAPEUTISCHE 1H-PYRIDO[4,3-b]INDOLE |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
EP1314554A1 (fr) | 2001-11-23 | 2003-05-28 | Kba-Giori S.A. | Dispositif de décollage d'éléments de sécurité |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
US20040092534A1 (en) | 2002-07-29 | 2004-05-13 | Yam Nyomi V. | Methods and dosage forms for controlled delivery of paliperidone |
AU2003257062A1 (en) | 2002-08-02 | 2004-02-23 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
US20040142970A1 (en) | 2002-11-01 | 2004-07-22 | Kathryn Chung | Treatment of hyperkinetic movement disorder with donepezil |
US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
EP1581221B1 (fr) | 2002-12-19 | 2011-05-18 | Bristol-Myers Squibb Company | Gamma-carbolines tricycliques substituees utilisees comme agonistes et antagonistes du recepteur de la serotonine |
CA2532397A1 (fr) | 2003-07-21 | 2005-02-03 | Smithkline Beecham Corporation | Sel d'acide (2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-1-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonique, et certaines de ses formes crristallines anhydres |
US7109064B2 (en) | 2003-12-08 | 2006-09-19 | Semiconductor Components Industries, L.L.C. | Method of forming a semiconductor package and leadframe therefor |
JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
WO2005095396A1 (fr) | 2004-03-05 | 2005-10-13 | Pharma C S.A. | Derives de 8-phenoxy-$g(g) carboline |
US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
EP1793671B1 (fr) | 2004-09-20 | 2011-04-27 | Mount Sinai School of Medicine | Utilisation de memantine (namenda) pour traiter l'autisme, les etats compulsifs et impulsifs |
MX2007002459A (es) | 2004-09-21 | 2007-05-04 | Pfizer Prod Inc | N-metilhidroxietilamina util en el tratamiento de afecciones del snc. |
US7614727B2 (en) | 2004-09-30 | 2009-11-10 | Fujifilm Corporation | Liquid ejection head, manufacturing method thereof, and image forming apparatus |
NZ555476A (en) | 2004-12-15 | 2009-09-25 | Hoffmann La Roche | Bi- and tricyclic substituted phenyl methanones as glycine transporter I (GLYT-1) inhibitors for the treatment of alzheimerÆs disease |
EP1848433A2 (fr) | 2005-01-25 | 2007-10-31 | Celgene Corporation | Methodes et compositions utilisant 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione |
EP1919287A4 (fr) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | Composés organiques pour traiter un signald'activité réduit du récepteur de la dopamine |
CN101309917B (zh) | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂 |
CN101370775A (zh) | 2006-01-13 | 2009-02-18 | 惠氏公司 | 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚 |
US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
EP2068872A1 (fr) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinaisons contenant un dérivé de 4-acylaminopyridine |
CN101796051B (zh) * | 2007-03-12 | 2013-11-06 | 细胞内治疗公司 | 与取代的杂环稠合的γ-咔啉的合成 |
WO2009017836A1 (fr) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Procédés et compositions destinés au traitement de la schizophrénie par thérapie de combinaison d'antipsychotiques |
DK2180844T3 (en) | 2007-08-02 | 2018-04-23 | Insys Dev Co Inc | SUBLINGUAL FENTANYLSPRAY |
EP2190844B3 (fr) | 2007-08-15 | 2013-07-17 | Arena Pharmaceuticals, Inc. | Dérivés d'imidazo[1,2-a]pyridine utilisés comme modulateurs du récepteur sérotoninergique 5-ht2a dans le traitement des troubles qui lui sont associés |
US20090209608A1 (en) | 2007-08-29 | 2009-08-20 | Protia, Llc | Deuterium-enriched asenapine |
US20090076159A1 (en) | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched eplivanserin |
AU2009212065B2 (en) | 2008-02-05 | 2014-03-20 | Clera Inc. | Compositions and methods for alleviating depression or improving cognition |
CN101986784A (zh) | 2008-02-07 | 2011-03-16 | 先灵公司 | 基因工程tslpr抗体 |
MX2010010024A (es) | 2008-03-12 | 2010-11-09 | Intra Cellular Therapies Inc | Solido de gamma-carbolinas fusionadas con heterociclos substituidos. |
CN105168219B (zh) | 2008-05-27 | 2018-11-20 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
US8309772B2 (en) | 2008-07-31 | 2012-11-13 | Celanese International Corporation | Tunable catalyst gas phase hydrogenation of carboxylic acids |
US20100159033A1 (en) | 2008-09-29 | 2010-06-24 | Auspex Pharmaceuticals, Inc. | Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor |
WO2011044019A1 (fr) | 2009-10-05 | 2011-04-14 | Bristol-Myers Squibb Company | Métabolites du (r)-1-(4-(4-fluoro-2-méthyl-1h-indol-5-yloxy)-5-méthylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol |
NZ731621A (en) * | 2009-12-04 | 2019-01-25 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
TWI582092B (zh) | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物 |
AU2011343429B2 (en) | 2010-12-16 | 2016-10-20 | Sunovion Pharmaceuticals Inc. | Sublingual films |
US8697700B2 (en) | 2010-12-21 | 2014-04-15 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof |
WO2012177929A2 (fr) | 2011-06-24 | 2012-12-27 | Amylin Pharmaceuticals, Inc. | Procédés pour traiter le diabète avec des formulations à libération prolongée d'agonistes de procédé glp-1 |
RU2014145682A (ru) | 2012-04-14 | 2016-06-10 | Интра-Селлулар Терапиз, Инк | Органические соединения |
AU2013286823B2 (en) | 2012-07-06 | 2017-12-14 | Monash University | Immunological reagents and uses therefor |
US10118926B2 (en) | 2012-09-14 | 2018-11-06 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
EP2968320B1 (fr) | 2013-03-15 | 2020-11-11 | Intra-Cellular Therapies, Inc. | Composés organiques |
WO2015038327A1 (fr) | 2013-09-10 | 2015-03-19 | Insys Pharma, Inc. | Spray sublingual contenant de la buprénorphine |
WO2015085004A1 (fr) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Nouveaux procédés |
KR20220054908A (ko) | 2014-04-04 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
EP3125892A4 (fr) | 2014-04-04 | 2017-12-27 | Intra-Cellular Therapies, Inc. | Composés organiques |
WO2015191554A1 (fr) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Composés et leurs procédés d'utilisation pour traiter la schizophrénie |
KR20180014778A (ko) | 2015-06-03 | 2018-02-09 | 트리아스텍 인코포레이티드 | 제형 및 이의 용도 |
WO2017117514A1 (fr) | 2015-12-31 | 2017-07-06 | Tung Roger D | Iti-007 deutéré |
IL296884B2 (en) | 2016-01-26 | 2024-05-01 | Intra Cellular Therapies Inc | Condensed heterocyclic converted gamma carbonyls for use in the treatment of central nervous system disorders |
CN113754661A (zh) | 2016-03-25 | 2021-12-07 | 细胞内治疗公司 | 有机化合物 |
US20200392135A1 (en) | 2016-03-25 | 2020-12-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP3436016B1 (fr) | 2016-03-28 | 2022-04-27 | Intra-Cellular Therapies, Inc. | Nouveaux co-cristaux |
WO2017172784A1 (fr) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Nouveaux sels et cristaux |
US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
WO2018126143A1 (fr) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Composés organiques |
BR112019019875A2 (pt) | 2017-03-24 | 2020-04-22 | Intra Cellular Therapies Inc | novas composições e métodos |
EP3658144B1 (fr) | 2017-07-26 | 2022-01-26 | Intra-Cellular Therapies, Inc. | Composés pyridopyrroloquinoxalines, leurs compositions et utilisations en thérapie |
US11376249B2 (en) | 2017-07-26 | 2022-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
CA3102948A1 (fr) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Nouvelles methodes |
EP3833346A4 (fr) | 2018-08-08 | 2022-08-03 | Torralva Medical Therapeutics LLC | Compositions pour la prévention et l'inversion des effets d'opiacés et d'opioïdes, et leurs procédés d'utilisation |
US20220048910A1 (en) | 2018-12-21 | 2022-02-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
AU2019444588A1 (en) | 2019-05-07 | 2021-12-02 | Nirsum Laboratories, Inc. | Opioid receptor antagonist prodrugs |
-
2017
- 2017-01-26 IL IL296884A patent/IL296884B2/en unknown
- 2017-01-26 PT PT202157863T patent/PT3838274T/pt unknown
- 2017-01-26 PT PT177449105T patent/PT3407888T/pt unknown
- 2017-01-26 JP JP2018538850A patent/JP6995761B2/ja active Active
- 2017-01-26 HU HUE20215786A patent/HUE064667T2/hu unknown
- 2017-01-26 ES ES20215786T patent/ES2969145T3/es active Active
- 2017-01-26 WO PCT/US2017/015178 patent/WO2017132408A1/fr active Application Filing
- 2017-01-26 IL IL260653A patent/IL260653B2/en unknown
- 2017-01-26 KR KR1020187024393A patent/KR20180099905A/ko not_active Application Discontinuation
- 2017-01-26 MX MX2018009158A patent/MX2018009158A/es unknown
- 2017-01-26 ES ES17744910T patent/ES2863471T3/es active Active
- 2017-01-26 CN CN201780019593.8A patent/CN108883111B/zh active Active
- 2017-01-26 RU RU2018130727A patent/RU2743513C2/ru active
- 2017-01-26 IL IL309536A patent/IL309536A/en unknown
- 2017-01-26 AU AU2017211791A patent/AU2017211791B2/en active Active
- 2017-01-26 DK DK17744910.5T patent/DK3407888T3/da active
- 2017-01-26 BR BR112018015283-8A patent/BR112018015283B1/pt active IP Right Grant
- 2017-01-26 CA CA3011983A patent/CA3011983A1/fr active Pending
- 2017-01-26 EP EP20215786.3A patent/EP3838274B1/fr active Active
- 2017-01-26 PL PL17744910T patent/PL3407888T3/pl unknown
- 2017-01-26 PL PL20215786.3T patent/PL3838274T3/pl unknown
- 2017-01-26 HU HUE17744910A patent/HUE053737T2/hu unknown
- 2017-01-26 EP EP17744910.5A patent/EP3407888B1/fr active Active
- 2017-01-26 CN CN202111095870.8A patent/CN113786407B/zh active Active
- 2017-01-26 DK DK20215786.3T patent/DK3838274T3/da active
- 2017-07-26 US US15/660,615 patent/US10245260B2/en active Active
-
2018
- 2018-07-26 MX MX2021010306A patent/MX2021010306A/es unknown
-
2019
- 2019-02-14 US US16/276,331 patent/US10799500B2/en active Active
-
2020
- 2020-09-09 US US17/015,883 patent/US11844757B2/en active Active
-
2021
- 2021-12-15 JP JP2021203529A patent/JP7234337B2/ja active Active
-
2023
- 2023-02-22 JP JP2023026571A patent/JP7471482B2/ja active Active
- 2023-11-06 US US18/502,460 patent/US20240165111A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011133224A1 (fr) * | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Composés organiques |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3407888A4 (fr) | Composés organiques | |
EP3407889A4 (fr) | Composés organiques | |
EP3658145A4 (fr) | Composés organiques | |
EP3125893A4 (fr) | Composés organiques | |
EP3125892A4 (fr) | Composés organiques | |
EP3564232A4 (fr) | Composé inhibiteur de signal bmp | |
EP3432688A4 (fr) | Élément électroluminescent organique | |
EP3325449A4 (fr) | Composés | |
EP3244462A4 (fr) | Élément électroluminescent organique | |
EP3658144A4 (fr) | Composés organiques | |
EP3279963A4 (fr) | Élément électroluminescent organique | |
EP3279961A4 (fr) | Élément électroluminescent organique | |
EP3244465A4 (fr) | Élément électroluminescent organique | |
EP3157926A4 (fr) | Composés organiques | |
EP3255692A4 (fr) | Élément électroluminescent organique | |
EP3377590A4 (fr) | Composés électrochromiques organiques solubles dans des solvants protogènes | |
EP3177627A4 (fr) | Composés organiques | |
EP3379593A4 (fr) | Élément électroluminescent organique | |
EP3562484A4 (fr) | Composés organiques | |
EP3226862A4 (fr) | Composés organiques | |
EP3464336A4 (fr) | Composés | |
EP3533799A4 (fr) | Composé | |
EP3399566A4 (fr) | Élément à électroluminescence organique | |
EP3544073A4 (fr) | Élément électroluminescent organique | |
EP3244464A4 (fr) | Élément électroluminescent organique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180827 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602017030491 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031498500 Ipc: C07D0471160000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190529 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/00 20060101ALI20190523BHEP Ipc: C07D 471/16 20060101AFI20190523BHEP Ipc: A61K 31/4985 20060101ALI20190523BHEP Ipc: A61K 31/445 20060101ALI20190523BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40000759 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200401 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200721 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017030491 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1349822 Country of ref document: AT Kind code of ref document: T Effective date: 20210115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 3407888 Country of ref document: PT Date of ref document: 20210319 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20210312 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: PHARMA PATENTS INTERNATIONAL AG, CH Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210329 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210330 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210330 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E053737 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210126 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210430 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017030491 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2863471 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20211001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1349822 Country of ref document: AT Kind code of ref document: T Effective date: 20201230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210430 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20230111 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230120 Year of fee payment: 7 Ref country code: IT Payment date: 20230110 Year of fee payment: 7 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230517 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231207 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20231213 Year of fee payment: 8 Ref country code: NL Payment date: 20231215 Year of fee payment: 8 Ref country code: IE Payment date: 20231211 Year of fee payment: 8 Ref country code: FR Payment date: 20231212 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20231211 Year of fee payment: 8 Ref country code: BE Payment date: 20231219 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240208 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20231227 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201230 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20231213 Year of fee payment: 8 Ref country code: DE Payment date: 20231205 Year of fee payment: 8 Ref country code: CZ Payment date: 20240117 Year of fee payment: 8 Ref country code: CH Payment date: 20240202 Year of fee payment: 8 Ref country code: PT Payment date: 20240124 Year of fee payment: 8 |